Pediatrix Medical Group reported fourth quarter 2025 results that were in line with revised upward expectations, showing solid same-unit revenue growth despite an increase in variable practice incentive compensation. The company achieved net revenue of $493.8 million, net income of $33.7 million, and Adjusted EPS of $0.50.

Pediatrix Medical Group delivered strong Q3 results, surpassing internal expectations. The company benefited from favorable reimbursement dynamics and higher patient acuity, resulting in significant growth in same-unit revenue and profitability.

Pediatrix Medical Group reported strong first quarter 2025 results with net revenue of $458.4 million, net income of $20.7 million, and adjusted EBITDA of $49.2 million. The company raised its full-year 2025 Adjusted EBITDA outlook range to $220 million to $240 million.

Pediatrix Medical Group reported strong fourth-quarter results, driven by top-line outperformance, completion of portfolio restructuring, and overhead expense reductions. Net revenue increased to $502.4 million, with a net income of $30.5 million, or $0.36 per share. Adjusted EPS was $0.51, and Adjusted EBITDA reached $68.7 million.

Pediatrix Medical Group reported a net revenue of $511 million and earnings per share of $0.23 for the third quarter of 2024. The company's operating results modestly exceeded expectations, driven by strength in same-unit revenue.

Pediatrix Medical Group reported second-quarter results exceeding expectations with stable patient volumes, improved payor mix, and operating efficiencies. The company reported a net revenue of $504 million, a net loss of $153 million, and an adjusted EBITDA of $58 million.

Pediatrix Medical Group reported first quarter results with a net revenue of $495.1 million and earnings of $0.05 per share. The company's Adjusted EPS was $0.20 and Adjusted EBITDA was $37.2 million.

Pediatrix Medical Group reported a net revenue of $496.4 million for Q4 2023, a decrease from $513.8 million in the prior-year period. The company experienced a loss from continuing operations of $124.3 million, or $1.50 per share, compared to an income of $24.0 million, or $0.29 per share, in Q4 2022. Adjusted EPS from continuing operations was $0.32, down from $0.47 in the same period last year. Adjusted EBITDA from continuing operations was $50.8 million, compared to $66.5 million for the prior-year period.

Pediatrix Medical Group reported net revenue of $507 million and income from continuing operations of $21 million, or $0.26 per share, for the three months ended September 30, 2023. Adjusted EPS from continuing operations was $0.32. The company anticipates its 2023 Adjusted EBITDA to be in the range of $200 million to $210 million.

Pediatrix Medical Group reported second-quarter earnings from continuing operations of $0.34 per share, with an adjusted EPS of $0.39. Net revenue was $500.6 million, compared to $486.0 million for the prior-year period. The company's overall same-unit revenue increased by 3.2 percent.

Pediatrix Medical Group reported first quarter earnings with a net revenue of $491 million and an Adjusted EBITDA of $40 million. The company's EPS was $0.17, and the non-GAAP Adjusted EPS was $0.23.

Pediatrix Medical Group reported Q4 2022 results with a net revenue of $514 million, income from continuing operations of $36 million, and Adjusted EBITDA of $66 million. Adjusted EPS from continuing operations was reported at $0.47 per share.

Pediatrix Medical Group reported a net revenue of $490 million and an EPS of $0.35 for the third quarter of 2022. The company's operating results were impacted by challenges in billing and collections, as well as headwinds in volumes and payor mix. Adjusted EBITDA was reported as $58 million.

Pediatrix Medical Group reported a net revenue of $486 million for the second quarter of 2022, with earnings from continuing operations at $0.36 per share and Adjusted EPS at $0.47. The company's revenue growth was driven by net acquisition activity, slightly offset by a same-unit revenue decrease of 1.3 percent.

Mednax reported net revenue of $482 million and a loss from continuing operations of $21 million. Adjusted EPS from continuing operations was $0.33, and Adjusted EBITDA was $51 million. The company's bottom line results were in line with expectations, reflecting continued patient volume growth.

Mednax reported a solid fourth quarter, with net revenue of $499 million and Adjusted EPS from continuing operations of $0.52. The company's focus on women's, newborns', and children's health contributed to the positive results.

Mednax reported a net revenue of $493 million and income from continuing operations of $32 million, or $0.37 per share, for the third quarter of 2021. Adjusted EPS from continuing operations was $0.46. The company also invested in Brave Care to accelerate activities in pediatric primary and urgent care.

Mednax reported strong second quarter results with net revenue of $473 million and income from continuing operations of $31 million. Adjusted EPS from continuing operations was $0.41.

Mednax reported Q1 2021 earnings with a net revenue of $447 million and an income from continuing operations of $5 million. Adjusted EPS from continuing operations was $0.24.

Mednax, Inc. reported earnings from continuing operations of $0.05 per share for the three months ended December 31, 2020. On a non-GAAP basis, Mednax reported Adjusted EPS from continuing operations of $0.25. Net revenue for the quarter was $417 million and income from continuing operations was $4 million.

MEDNAX reported a net loss of $41.0 million, or $0.49 per share, for the third quarter of 2020. On a non-GAAP basis, Adjusted EPS from continuing operations was $0.37. Net revenue from continuing operations was $461 million.

MEDNAX reported a net loss of $8.03 per share but an adjusted EPS of $0.32 from continuing operations. Net revenue was $509 million, net income was $8 million, and adjusted EBITDA was $65 million for the second quarter of 2020.

MEDNAX reported a challenging first quarter, marked by a net revenue of $846 million but a loss of $16 million. The company's performance was significantly impacted by the COVID-19 pandemic, which reduced consolidated revenue by approximately $40 million compared to forecasted revenue. Additionally, MEDNAX completed the sale of American Anesthesiology subsequent to the end of the quarter.

MEDNAX reported Q4 2019 results with net revenue of $905 million and earnings from continuing operations of $0.40 per share. Adjusted EPS from continuing operations was $0.91. The company also announced a unilateral, multi-state termination by UnitedHealth Group.